News

Preliminary data from the Cook/Selexis-sponsored proof-of-concept program has been published in the June issue of BioProcess International in an article titled, "Rapid Development and Scale-Up Through Strategic Partnership:

As part of the option deal, Aurigene will receive an upfront payment from Orion, followed by a licensing fee, milestones and royalties upon exercising the option at the

According to the company, early launch of these products was fueled by the strong feedback from many national retailers in the US. The company has been working with

Ligand’s IRAK4 is a major signaling kinase that becomes inappropriately activated in tumors that carry certain oncogenic mutations of MYD88, which can be found in most patients with

As part of the deal, Abbott will acquire Garden Hills, which currently owns more than 80% of Veropharm, for about $395m or $495m, depending on Garden Hills’ share

The company said that BNC375 and related compounds have displayed potent efficacy in animal cognitive impairment models. As part of the deal, Merck will provide funding for all

ILUVIEN (190 micrograms intravitreal implant in applicator) has been designated a C Class product in Italy and it will be available initially to private paying patients. The company

The EMA orphan drug status provides a number of benefits, including ten years of market exclusivity from product launch in the EU, fee reductions, and access to the

Dimension Therapeutics is focused on developing new adeno-associated virus (AAV) gene therapy treatments for rare diseases. Bayer HealthCare member of the Executive Committee and head of Global Drug